Abstract:Lappaconitine instead of its hydrobromide salts has been encapsulated in poly (lactide-co-glycolide) acid (PLGA) microspheres by the simple o/w emulsion solvent evaporation technique. The effects of several variables including emulsifier (polyvinyl alcohol, PVA) concentration, stirring speed, PLGA concentration and drug/polymer mass ratios on quality of microspheres have been investigated. The particle size and size distribution can be controlled by PVA concentration, stirring speed and PLGA concentration. The entrapment efficiency and the burst release of lappaconitine from drug-loaded microspheres were dominantly affected by the drug/polymer mass ratio and PVA concentration. The best parameters of formulation were 1.5% PVA, the PLGA concentration of 50 g/L, and the stirring speed of 800 rpm and drug/polymer of 1:5. The optimized formulation has a mean particle size of 19.3+/-0.93 mu M, mean entrapment efficiency of 70.77+/-3.23% and mean drug loading of 11.45+/-0.47%. Based on the optimized parameters of formulation, the effects of oil/aqueous solubility partition ratio of drug on entrapment efficiency of drug-loaded microspheres prepared by o/w emulsion solvent evaporation were further studied. A good linear relation existed between the partition ratio and entrapment efficiency. The optimized microspheres were characterized by SEM, FT-IR, DSC and XRD. SEM shows spherical and smooth surface and uniform size distribution. The results of DSC, FT-IR study reveal no interaction between drug and polymer. The results of the XRD study indicate lappaconitine trapped in microsphere exists in form of an amorphous or disordered crystalline status in polymer matrix. The in vitro release models were evaluated with two different groups of drug-loaded microspheres including microspheres washed with distilled water and 0.01N HCL, respectively. The drug release profile of lappaconitine-loaded microspheres washed with distilled water agreed with zero order equation and that of the latter better agreed with first order equation.

Study on entrapment efficiency, drug release in vitro and stability of Crebanine long circulating liposome

Study on the liposome/water partition coefficient for breviscapine and its application

Effect of Peg2000 on Drug Delivery Characterization from Solid Lipid Nanoparticles

Lappaconitine-loaded microspheres for parenteral sustained release: effects of formulation variables and in vitro characterization.

Determination of Contents of Functional Epirubicin Liposomes and Invitro Release Rate

The Formulation of Epirubicin Hydrochloride Long-Circulating Thermosensitive Liposomes and Drug Re-lease in Vitro

Studies on the preparation and release of neferine nanoliposomes in vitro

Development of Ionic-Complex-based Nanostructured Lipid Carriers to Improve the Pharmacokinetic Profiles of Breviscapine

Preparation and Entrapment Efficiency Determination of Solid Lipid Nanoparticles Loaded Levodopa

Study on Preparation of Breviscapine Liposomes and Chemicophysical Properties

Determination of entrapment efficiency for liposomal formulation of breviscapine using ultrafiltration-HPLC method

Preparation and in vitro evaluation of liposomal chloroquine diphosphate loaded by a transmembrane pH-gradient method

Comparative study on the release behaviors of irinotecan loaded liposomes with two active loading methods

[Determination of Entrapment Efficiency of Breviscapine Nanoliposomes].

Optimized preparation, characterization and biodistribution in heart of breviscapine lipid emulsion.

Study on Encapsulation Efficiency and in Vitro Release of Baicalin Liposomes

[Preparation and Study in Vitro of Long-Circulating Nanoliposomes of Curcumin].

Characterization, biodistribution and targeting evaluation of breviscapine lipid emulsions following intravenous injection in mice.

Preparation of Ropivacaine Hydrochloride Multivesicular Liposomes and Release in Vitro

Determination of Entrapment Efficiency of the Stealth Matrine Liposomes and Study on Its Release in Vitro

Preparation of oxaliplatin liposome and in vitro drug-release